To summarize, during the period under review there have been considerable advances in our understanding of how antigen is associated with MHC on the surface of a presenting cell. Basic rules which govern this association have been confirmed as including both the nature and the configuration of the antigen. Although the different processing pathways which generate the antigen-MHC complex have remained ill-defined, it is now much more clear what the optimum end point of such processing must be. As a result of these studies, several new questions can now be addressed in the field of antigen presentation. During the next few years it should become apparent why there should be such an unusual differential presenting cell requirement for T cells which are expressing a selected variable region of the T cell receptor and whether other T cells expressing different receptors have different optimum presentation requirements. It should become clear also whether different antigens have similar residues at the sides of the alpha helix which are important in MHC binding, and whether the sheet or helix models are more important in vivo. A rational explanation for dominance of alloreactivity has been proposed, and kinetic studies of self-MHC processing are essential to define this further. Furthermore the possibility of an antigen unmasking an MHC polymorphism (which in turn could influence presentation) will have to be considered seriously in the pathogenesis of auto-immunity.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0952-7915(88)90004-0 | DOI Listing |
Adv Sci (Weinh)
January 2025
Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411, Estonia.
In triple-negative breast cancer (TNBC), pro-tumoral macrophages promote metastasis and suppress the immune response. To target these cells, a previously identified CD206 (mannose receptor)-binding peptide, mUNO was engineered to enhance its affinity and proteolytic stability. The new rationally designed peptide, MACTIDE, includes a trypsin inhibitor loop, from the Sunflower Trypsin Inhibitor-I.
View Article and Find Full Text PDFInt Med Case Rep J
January 2025
Kilimanjaro Christian Medical University College of Tumaini University, Moshi, Tanzania.
Background: Neurocysticercosis (NCC) and Acquired Human Immunodeficiency Syndrome (AIDS) are both highly prevalent in Africa. Clinical presentation of NCC ranges from asymptomatic to manifestations, including epileptic seizures, severe progressive headache, and focal neurological deficits. It is influenced by the number, size, location, and stage of the cysts, as well as the parasite's potential to cause inflammation and the immunological response of the host.
View Article and Find Full Text PDFFront Immunol
January 2025
Centro de Investigaciones Oncológicas (FUCA), Fundación Cáncer, Ciudad Autónoma de Buenos Aires, Argentina.
VACCIMEL is a therapeutic cancer vaccine composed of four irradiated allogeneic human melanoma cell lines rationally selected to cover a wide range of melanoma tumor-associated antigens (TAA). We previously demonstrated that vaccination in the adjuvant setting prolonged the distant-metastasis-free survival of cutaneous melanoma patients and that T cells reactive to TAA and the patient's private neoantigens increased during treatment. However, immune responses directed to vaccine antigens that may arise from VACCIMEL's somatic mutations and human polymorphisms remain unexplored.
View Article and Find Full Text PDFAdv Mater
January 2025
Sichuan Provincial Key Laboratory for Human Disease Gene Study and the Center for Medical Genetics, Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, P. R. China.
Tumor vaccines that activate the autologous immune system to eliminate tumor cells represent a promising approach in cancer immunotherapy. However, challenges such as tumor heterogeneity, limited antigen selection, insufficient antigen presentation, and the slow onset of de novo immune responses have resulted in poor universality and suboptimal response rates. In contrast, pathogen-specific pre-existing immunity acquired through infection or vaccination, can rapidly generate a more potent and enduring immune response upon re-encounter with the same antigen.
View Article and Find Full Text PDFFront Immunol
January 2025
School of Public Health and Health Management, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Introduction: The high percentage of Omicron breakthrough infection in vaccinees is an emerging problem, of which we have a limited understanding of the phenomenon.
Methods: We performed single-cell transcriptome coupled with T-cell/B-cell receptor (TCR/BCR) sequencing in 15 peripheral blood mononuclear cell (PBMC) samples from Omicron infection and naïve with booster vaccination.
Results: We found that after breakthrough infection, multiple cell clusters showed activation of the type I IFN pathway and widespread expression of Interferon-stimulated genes (ISGs); T and B lymphocytes exhibited antiviral and proinflammatory-related differentiation features with pseudo-time trajectories; and large TCR clonal expansions were concentrated in effector CD8 T cells, and clonal expansions of BCRs showed a preference for IGHV3.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!